Latest Product Development News

Pengana Capital Group reported a statutory loss of $5.6 million for FY26 despite a 14% rise in funds under management, driven by upfront costs linked to new product launches and expanding private credit platforms.

Lynas Rare Earths delivered a record A$977.9 million revenue and A$222.4 million net profit in FY26, underpinned by strong rare earth production, strategic supply agreements, and a 10-year Malaysian licence renewal.

WiseTech Global posted a record $1.4 billion in revenue for FY26, driven by the e2open acquisition and AI-led efficiencies, while underlying net profit rose 29%. The company outlines a confident FY27 growth outlook amid ongoing integration and innovation.

Epiminder Limited reported a $42.7 million loss for FY26, driven by clinical trial and product development costs following a $125 million IPO. The company progresses its FDA-approved Minder implantable EEG monitor with a pivotal US trial and next-gen device on track for 2028 launch.

Netwealth Group posted record FY26 revenue of $391 million, up 21%, with adjusted net profit rising 16.2% to $135.4 million after excluding $105 million in First Guardian compensation. The company declared a fully franked 21-cent final dividend, maintaining a 9.1% increase in total dividends.

Atturra Limited’s FY26 results reveal a sharp net loss driven by a $22.8 million goodwill impairment, overshadowing a 17% revenue increase to $351.8 million. The company is banking on AI and strategic acquisitions to fuel a turnaround in FY27.

Monvia Limited reported a $28.7 million revenue year with a $6.9 million adjusted EBITDA, exceeding IPO forecasts, while renewing a $60 million contract with MetLife and completing its ASX listing.

Complii FinTech Solutions expanded into institutional markets with a major contract, raised $2 million via convertible notes, and facilitated $22.48 billion capital raising on its platform in FY26.

Terragen Holdings posted a slight increase in net loss to AUD 3.75 million for FY2026, while advancing key commercial trials and securing a $7 million equity raise to fuel growth.

HighCom Limited’s FY26 results reveal a sharp revenue drop and widening loss driven by a US Government shutdown, but a strengthened leadership team and expanded global sales pipeline set the stage for recovery.

ARB Corporation's FY2026 results show a 3.8% revenue dip and 5.2% profit decline amid challenging 4x4 sales, while international expansion and engineering investment underpin future growth.

Genetic Signatures narrowed its FY2026 net loss by 30% to $14 million amid a strategic overhaul, signing a key 10-year supply deal with Denmark’s Hvidovre Hospital and resetting its US market approach.